<SEC-DOCUMENT>0001833141-25-000038.txt : 20251112
<SEC-HEADER>0001833141-25-000038.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112111016
ACCESSION NUMBER:		0001833141-25-000038
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251112
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		251470629

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk11x12x2025.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6af450a177664cce82d9ff33e59bd6cb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">For the month of November, 2025.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">November 12, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Greg Cavers&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Greg Cavers</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a11-12x2025jefferieslondon.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated November 12, 2025</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a11-12x2025jefferieslondon.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9324fdc6c4314c22972d5dd4b9f51dfd_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">  </font></div><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:120px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin to Participate in the Jefferies Global Healthcare Conference in London</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; November 12, 2025 &#8211; </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NYSE American&#58;CYBN) (Cboe CA&#58;CYBN) (&#8221;Cybin&#8221; or the &#8220;Company&#8221;), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that George Tziras, Cybin&#8217;s Chief Business Officer, will present at the Jefferies Global Healthcare Conference, taking place November 17-20, 2025, in London, UK. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The presentation will be webcast live on Monday, November 17, 2025, at 12&#58;30 p.m. GMT (7&#58;30 a.m. ET). To listen to the event, please </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">click here</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> to access the webcast. The archived webcast will also be available on the Company&#8217;s investor relations website on the </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Events &#38; Presentations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> page.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, and Ireland.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor Contact&#58;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Josh Barer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">astr partners</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Managing Director</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(908) 578-6478</font></div><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">josh.barer&#64;astrpartners.com</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">George Tziras<br>Chief Business Officer<br>Cybin Inc.<br>1-866-292-4601<br></font><font style="background-color:#ffffff;color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;&#8211; or &#8211;&#160;</font><font style="background-color:#ffffff;color:#467886;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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MX+XF2J$\^4 <A:@"!<P\=C&QF_R\B3JQH<$#::\P%2*+%\;1B[^9]@]3(>I
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MA6GO[&]Z1Y@.$KJ);!JF[M"B2"P/WJ<HY!^,F2^8?AFF"R&XDMBHK/,!4%O
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M)$MA:Y_!$OHV>1>7Y0%QS(&5'AFJ74'Q>%_!$JC)]"KR]SJ.X^B5.[YE#Y9
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MG":4; I=$W10\2JE^(QI3%G%0HR.V@+F3>(HVD%3V#>$:3:>3C>U@REST^_
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M3/N&J1!"](,"INB2Y\:Q#7N;#@Q3(83H#P5,T27GF=JTX**SR9%A*H00_:*
M*;KF':9'F-9/7LWF#R9Z9KYW\DH((2I  5/TP;&FFY@.,9UF(B'H;!/>L$>8
A;FKZE$D((2KA<I?[_[P*ZV0DJ0MG     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
